TD Private Client Wealth LLC Has $6.97 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

TD Private Client Wealth LLC cut its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,642 shares of the medical research company's stock after selling 2,367 shares during the period. TD Private Client Wealth LLC's holdings in Amgen were worth $6,973,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Lantz Financial LLC lifted its position in Amgen by 5.1% during the 2nd quarter. Lantz Financial LLC now owns 1,779 shares of the medical research company's stock valued at $556,000 after purchasing an additional 87 shares during the period. Great Valley Advisor Group Inc. boosted its stake in Amgen by 9.7% in the second quarter. Great Valley Advisor Group Inc. now owns 7,772 shares of the medical research company's stock valued at $2,429,000 after acquiring an additional 686 shares during the last quarter. Baader Bank Aktiengesellschaft grew its holdings in Amgen by 97.1% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 1,577 shares of the medical research company's stock worth $492,000 after acquiring an additional 777 shares during the period. DB Fitzpatrick & Co Inc raised its position in shares of Amgen by 145.4% during the 2nd quarter. DB Fitzpatrick & Co Inc now owns 4,311 shares of the medical research company's stock valued at $1,347,000 after acquiring an additional 2,554 shares during the last quarter. Finally, Corundum Group Inc. lifted its stake in shares of Amgen by 111.2% in the 2nd quarter. Corundum Group Inc. now owns 4,113 shares of the medical research company's stock valued at $1,285,000 after purchasing an additional 2,166 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Down 0.8 %

NASDAQ AMGN traded down $2.34 during trading hours on Wednesday, hitting $273.41. 4,491,709 shares of the company traded hands, compared to its average volume of 2,615,041. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The business's 50-day moving average is $304.80 and its 200-day moving average is $315.45. The stock has a market capitalization of $146.97 billion, a price-to-earnings ratio of 34.83, a P/E/G ratio of 3.02 and a beta of 0.55. Amgen Inc. has a twelve month low of $257.80 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to analysts' expectations of $8.50 billion. During the same period last year, the business earned $4.96 earnings per share. The firm's revenue was up 23.2% on a year-over-year basis. Sell-side analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend is Friday, February 14th. Amgen's dividend payout ratio (DPR) is 115.24%.

Analysts Set New Price Targets

AMGN has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft dropped their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Wolfe Research initiated coverage on shares of Amgen in a report on Friday, November 15th. They set a "peer perform" rating for the company. Leerink Partners cut their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. TD Cowen lifted their price target on shares of Amgen from $381.00 to $383.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Amgen has an average rating of "Hold" and a consensus price target of $319.68.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.